Monoamine-dependent, opioid-independent antihypersensitivity effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a postoperative pain model in rats.
The neurotransmitters serotonin (5-HT) and noradrenaline (NA) have important roles in suppressing nociceptive transmission in the spinal cord. In the present study, we determined the efficacy and nature of the antihypersensitivity effects of milnacipran, a 5-HT and NA reuptake inhibitor (SNRI), in the spinal cord in a rat model of postoperative pain. Sprague-Dawley rats were used in all experiments. An incision was made on the plantar aspect of the hind paw. Mechanical hypersensitivity was measured by determining the withdrawal threshold to von Frey filaments applied to the paw. Drugs were administered intrathecally 24 h after paw incision. Microdialysis studies of the dorsal horn of the lumbar spinal cord were also performed to measure 5-HT and NA levels after systemic injection of milnacipran. Milnacipran (1-30 microg) produced dose-dependent antihypersensitivity effects. The effect lasted 6 h after the 30-microg injection. Doses of 30 microg or less produced no abnormal behavior. The peak antihypersensitivity effect of 10 microg of milnacipran was blocked by intrathecal pretreatment with antagonists of the alpha(2)-adrenoceptor (idazoxan; 30 microg) or 5-HT receptors (methysergide; 30 microg). Intrathecal pretreatment with 30 microg of naloxone, a mu-opioid receptor antagonist, did not reverse the effect of milnacipran. Isobolographic analysis indicated antinociceptive synergism between milnacipran and morphine. Microdialysis studies revealed that milnacipran increased both 5-HT and NA levels in the spinal dorsal horn. These findings suggest that the antihypersensitivity effect of intrathecal milnacipran in the postoperative pain model is monoamine-mediated. Combined administration of an SNRI with morphine might be a promising treatment to suppress postoperative hypersensitivity.
Obata
Hideaki
H
Department of Anesthesiology, Gunma University Graduate School of Medicine, 3-39-22 Showa, Maebashi, Gunma 371-8511, Japan. hobata@showa.gunma-u.ac.jp
Kimura
Masafumi
M
Nakajima
Kunie
K
Tobe
Masaru
M
Nishikawa
Koichi
K
Saito
Shigeru
S
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D015306:Biogenic Monoamines / Q000502:physiology*; D003521:Cyclopropanes / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D018409:Foot Injuries / Q000150:complications; D006930:Hyperalgesia / Q000139:chemically induced*; D008297:Male; D017551:Microdialysis; D000078764:Milnacipran; D009020:Morphine / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D010147:Pain Measurement / Q000187:drug effects; D010149:Postoperative Pain / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000187:drug effects*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors; D012701:Serotonin / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism
D018759:Adrenergic Uptake Inhibitors; D000701:Analgesics, Opioid; D015306:Biogenic Monoamines; D003521:Cyclopropanes; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D012701:Serotonin; D009020:Morphine; D000078764:Milnacipran; D009638:Norepinephrine